Effect of paclitaxel in combined with chemoradiotherapy in inhibiting the cell proliferation of breast cancer in the middle and later stage and the complication prevention measures

• Main Authors: Wei Huang, Jia-Yao Dong, Cheng-Yu Zhou, Xin-Fa Yu
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2016-07-01
• Series: Journal of Hainan Medical University
• Subjects: Paclitaxel; Chemoradiotherapy; Breast cancerm; Cell proliferation
• Online Access: http://www.hnykdxxb.com/PDF/201614/38.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To study the effect of paclitaxel in combined with chemoradiotherapy in inhibiting the cell proliferation of breast cancer in the middle and later stage and the complication prevention measures. Methods: A total of 74 patients with middle-advanced stage breast cancer who were admitted in our hospital from March, 2011 to February, 2012 were included in the study and divided into the experiment group and the control group according to the extraction method with 37 cases in each group. The patients in the control group were given the conventional radiotherapy, while the patients in the experiment group were given paclitaxel in combined with chemoradiotherapy. The expression levels of BaxmRNA and p53 of MCF-7 cell before and after treatment in the two groups were compared. The improvement of living qualities, the clinical efficacy, and the adverse reactions in the two groups were analyzed. Results: After treatment, the overall response rate in the experiment group [72.97% (27/37)] was significantly higher than that in the control group [40.54% (15/37)]. After treatment, the expression levels of BaxmRNA and p53 of MCF-7 cell in the experiment group were significantly higher than those in the control group. The increasing rate of living qualities in the experiment group [62.16% (23/37)] was significantly higher than that in the control group [18.92% (7/37)]. The occurrence rates of adverse reactions in the experiment group and the control group were [13.51% (5/37)] and [16.22% (6/37)], respectively, and the comparison was not statistically significant. Conclusions: Paclitaxel in combined with chemoradiotherapy in the treatment of middle-advanced stage breast cancer can effectively inhibit the proliferation of MCF-7, and enhance the living qualities, with a preferable clinical efficacy.